Multiple teams report insights and research on opportunities to improve cancer treatment outcomes
BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center physician-scientists and researchers will present new research on emerging treatment options and population health at the 2023 annual meeting of the American Association for Cancer Research, taking place in Orlando, Florida, from April 14-19.
Prasenjit Dey, PhD, Associate Professor of Oncology in the Department of Immunology, is an invited speaker for the major symposium “Cancer Ecosystem and the Microenvironment,” happening Wednesday, April 19. Dr. Dey will discuss major findings from his lab on type 2 or “helper” immune cells and how they interact with the ecosystem surrounding pancreatic cancers with the KRAS G12D mutation, one of the most prevalent genetic abnormalities in the disease.
“We found that this mutation increases expression of the Interleukin 33 protein, or IL33, in cancer cells. When IL33 is released, it recruits and activates these type 2 immune cells, which can stimulate tumor growth,” says Dr. Dey. “Genetic deletion of the protein or antimicrobial treatment can decrease type 2 immune cells from infiltrating pancreatic cancers with this mutation.”
“In my talk, I’ll highlight the implications of these discoveries and other exciting research in the field. This latest evidence strongly suggests that antifungal and anti-IL33 therapy can be combined with immune checkpoint inhibitor immunotherapy for more effective treatment approaches and outcomes,” says Dr. Dey.
Intersection of type 2 immunity and microbiome in cancer – Wednesday, April 19, Valencia A, Convention Center
Three groups of Roswell Park researchers will present posters on important topics in breast and esophageal cancer as well as cannabis use:
Arya Mariam Roy, MBBS, a hematology/oncology fellow, looked at National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program data over an eight-year period for patients with certain subtypes of breast cancer patients and their outcomes using chemotherapy. Her presentation is Benefit of chemotherapy in early-stage breast cancer with variant histology (Abstract 919/2)
Sarbajit Mukherjee, MD, Assistant Professor in Oncology, will present preliminary results on a phase 2 study looking at Trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC) (Abstract CT146/8)
Predoctoral trainee Michelle Goulette, alongside members of Roswell Park’s Department of Health Behavior, examine cannabis use in Roswell Park patients and survivors in Self-reported knowledge of ?9-tetrahydrocannabinol (THC) and cannabidiol (CBD) potency in cannabis products among cancer patients and survivors: Results from a survey of cannabis consumers at an NCI-designated cancer center (Abstract 6472/26)
Additional Poster Abstracts
Several additional teams from Roswell Park have been invited to present their research findings at AACR 2023:
- Shamshad Alam, PhD, Validating USP27X as a drug target in lung cancer
- Gabrielle Kennelley, Sex disparities in a murine model of BBN-induced bladder cancer
- Priyanka Rajan, Blockade of p38 MAPK reduces the tumor-induced immune suppressive microenvironment in metastatic breast cancer
- Sheeba Ba Aqeel, Incidence and survival outcomes of younger adults with colorectal cancers by age group: a SEER analysis
- Rongrong Wu, Kazuake Takabe, MD, Intratumoral tumor infiltrating lymphocytes is associated with cell proliferation and better survival but not with response to chemotherapy
- Jenny Gu, Prognostic value of CD20/CD73 ratio in sensitive and relapsed/refractory diffuse large B-cell lymphoma cell lines
- Mohammed Alruwaili, Evaluation of a novel two-drug combination strategy for p53-deficient colorectal and pancreatic cancers
- Meenalakshmi Chinnam, PhD, Requirement of MDM2 E3 ligase activity for regulating p53 during normal development, cell cycle regulation and genome integrity
- Celia DeJohn, Non-invasive imaging of hypoxia as a biomarker of immunotherapeutic efficacy in head and neck cancer
- Emily Oakley, Interstitial chemo-phototherapy for treatment of locally advanced hepatocellular carcinoma: A preclinical study
- Chieko Saito, PhD, Anti-CD19 antibody-drug conjugate therapy in B cell non-Hodgkin lymphoma
- Gal Shafirstein, DSc, Image-guided interstitial photodynamic therapy with palliative radiotherapy for ablating extrabronchial malignant central airway obstruction
- Moyi Wang, Lrig1 is a haplo-insufficient tumor suppressor and Lrig1-expressing cells can function as cells-of-origin of tumor development
- Wen Li, Further development of microRNA-34a therapeutics to target castration-resistant prostate cancer
- Opuriche Ibekwe, MBBS, DrPH, Can technology improve the quality and efficiency of multidisciplinary cancer conferences?
NOTE TO MEDIA: Rebecca Vogt, Media Relations Specialist, will be working in the onsite AACR 2023 press room. To coordinate coverage or arrange an interview with Roswell Park experts, please contact her at firstname.lastname@example.org or 716-548-0482.
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.